INTRODUCTION
Attention-deficit/hyperactivity disorder (ADHD) is a serious, chronic neurobehavioral disorder that occurs in children, adolescents, and adults. Although the disorder is commonly diagnosed during early or middle childhood in 2% to 18% of school-age children, 1 follow-up studies suggest that clinically significant symptoms persist into adolescence and adulthood. 2, 3 Current estimates place the prevalence of adult ADHD at 4.4% in the United States, 4 ,5 meaning that 6-10 million adults in the US may exhibit ADHD. 6 Adult ADHD patients, while experiencing symptoms that may evolve or change from those seen in childhood, have psychiatric comorbidities and ADHD-related functional and social impairments similar to those seen in their pediatric counterparts. 5, 7, 8 Despite its prevalence and associated morbidity, adult ADHD remains underdiagnosed and undertreated. 4 Currently, psychostimulants such as amphetamines and methylphenidate are indicated for the treatment of ADHD and are widely prescribed for the management of the disorder in adult patients.
Controlled studies show a similar pattern of response to stimulant treatment in children and adults with ADHD, with stimulant response rates >70% in adults given adequate doses. [11] [12] [13] [14] The advent of a number of long-acting stimulant formulations, such as mixed amphetamine salts extended release (MAS XR) and modified-release methylphenidate, has greatly simplified treatment and likely enhanced adherence by providing once-daily dosing. Sustained efficacy with MAS XR was recently reported in a large study of adults (n=255) with ADHD combined subtype. In the initial double-blind, 4-week, forced-dose-escalation phase of the study, adults were assigned to receive MAS XR 20, 40, or 60 mg. ADHD Rating Scale (ADHD-RS) scores were significantly improved beginning at week 1. At week 4, symptoms had been reduced from baseline by ~50%. 5 The degree of improvement was dose related; a larger proportion of subjects given 60 mg showed improvement from baseline than did subjects given 20 mg (65% versus 46%). In an open-label extension of this study, it was determined that with up to 18 months of dose-optimized MAS XR therapy, adults with ADHD experienced sustained symptom management. 15 A limitation of this and other previous studies of MAS XR in adults with ADHD is the application of narrow inclusion and exclusion criteria. In the 18-month study, for example, subjects were required to exhibit ADHD combined subtype (most common), and those with a significant mood or anxiety disorder were excluded. Because hyperactive symptoms may decline with age, adults with predominantly inattentive symptoms were likely excluded. 16 Because previous studies have investigated the efficacy of MAS XR in highly defined adult populations, the resulting data may not accurately characterize the broader adult ADHD patient population encountered in typical practice. To better examine the results of pharmacologic treatment in adults with ADHD in a more naturalistic, real-world clinical setting, the Quality of life, Effectiveness, Safety and Tolerability (QU.E.S.T.) trial has been undertaken. The primary objective of the QU.E.S.T. trial is to analyze the safety and efficacy of MAS XR (optimized, open-label doses) in a large sample of adults with ADHD drawn from naturalistic, community practice settings. The trial consists of two phases: a core 10-week phase and an additional 20-week extension phase. The trial has been initiated and enrollment is ongoing; investigators aim to enroll a total of 900 subjects from US and Canadian sites. The results of an interim analysis of the 10-week core investigation for the first 725 subjects enrolled in QU.E.S.T. are presented here.
METHODS

Subjects
Adults ≥18 years of age who satisfied Diagnostic and Statistical Manual of Mental Disorders, Fourth EditionText Revision (DSM-IV-TR) criteria 17 for a primary diagnosis of ADHD (including combined subtype, predominantly hyperactive/impulsive subtype, predominantly inattentive subtype, and "not otherwise specified") and who were willing and able to comply with study requirements were eligible to participate. Excluded were subjects who had a comorbid symptomatic psychiatric condition, such as any severe Axis I disorder or any Axis II disorder, that the investigator determined would interfere with MAS XR treatment or safety assessments, or had a history of failures to respond to adequate doses of amphetamines, or had a recent history (within the past 6 months) or suspicion of substance abuse or a positive urine drug result at screening. Also excluded were females who were pregnant or lactating, subjects with significant medical illness, and subjects with clinically significant laboratory, vital sign, or electrocardiographic (ECG) abnormalities at baseline or screening. Other exclusion criteria included a history of seizure disorder within the last 2 years, tic disorder, Tourette's syndrome, abnormal thyroid function, and cardiac disorder.
Study Design and Procedures
The QU.E.S.T. trial consists of two phases: a core, 10-week, multicenter, prospective, openlabel study with flexible MAS XR dosing (10-60 mg/day) and a 20-week extension phase. All study procedures and informed consent forms have been approved by institutional review boards at each participating research site. Subject enrollment in the trial is ongoing. The current report will describe only the 10-week core portion of the investigation. Procedures and findings from the 20-week extension phase will be reported separately.
Prior to any study procedures or assessments, investigators provided both written information and an oral explanation of the study procedures, and each subject provided written consent for study participation. The initial screening visit was followed by a washout period of ≥7 days to eliminate the presence of any restricted medications, including prior medications for ADHD as well as agents with central nervous system effects that could influence assessments during baseline and active treatment. Following the washout period, subject eligibility was reconfirmed at the baseline visit, baseline assessments were conducted, and open-label MAS XR was dispensed. Clinic visits during the 10-week active treatment period occurred at weeks 1, 2, 6, and 10 or upon early termination. Unscheduled visits could occur at any time at the discretion of the investigator for the purpose of MAS XR dose adjustment. A follow-up telephone call was conducted 30 days after the last dose of study drug to inquire about any new-onset serious adverse events and ongoing adverse events that might be study drug related.
Drug Dosing
On the day following baseline, MAS XR 20 mg/ day was initiated for all subjects. The recommended dose titration schedule was 20 mg/day during the first week, 40 mg/day starting the second week, and 60 mg/day starting the third week. The dose could be adjusted in 10-20-mg increments based on tolerability, efficacy, and clinical judgment. The maximum once-daily dose was 60 mg. At each scheduled clinic visit, the study drug was dispensed; subjects were instructed to return all unused drug at each visit.
Assessments
Efficacy was assessed using the ADHD-RS-IV 18 and the Clinical Global Impressions (CGI) scale. The ADHD-RS-IV is a clinician-administered semistructured questionnaire that consists of 18 items designed to reflect current symptomatology of ADHD based on DSM-IV-TR criteria. Each item is scored on a four-point scale from 0 (reflecting no symptoms) to 3 (reflecting severe symptoms), with total scores ranging from 0-54; separate scores may be generated for subscales measuring inattentiveness and hyperactivity/impulsivity. ADHD-RS-IV assessments were conducted at screening, baseline, and all scheduled clinic visits during active treatment. Improvement was measured on CGI-Improvement (CGI-I), a sevenpoint scale that grades symptoms from 1 (very much improved) to 7 (very much worse). Symptom severity was assessed on the CGI-Severity (CGI-S) scale (eg, a seven-point scale with 1=normal, 7=most severely ill) at baseline, and CGI-I was subsequently assessed at all scheduled clinic visits thereafter. Quality of life was assessed using the 36-item Short Form Health Survey questionnaire (version 2; SF-36 version 2™) 19 and the Medication Satisfaction Survey. The SF-36 version 2 is a validated questionnaire consisting of 36 items that assess quality of life across eight domains (general health, mental health, physical functioning, role-emotional, role-physical, social functioning, vitality, and bodily pain). Domain scores range from 0 (lowest quality of life) to 100 (highest quality of life), with higher scores reflecting a more favorable overall health status. Subjects completed the SF-36 version 2 at screening, baseline, and weeks 2, 6, and 10 or early termination. The 11-item patient-rated Medication Satisfaction Survey, designed to assess satisfaction with current ADHD treatment, was completed at the screening visit among subjects with a history of stimulant medications and by all subjects at visits on weeks 2, 6, and 10 or early termination.
Safety and tolerability were assessed based on spontaneously reported adverse events and reasons for early discontinuation. Vital signs and body weight were measured at each study visit. A full physical examination and clinical laboratory tests (hematology, chemistry, and urinalysis) were performed at screening and week 10 or early termination. A 12-lead ECG was conducted at screening, baseline, and week 10 or early termination.
Statistical Analyses
For analyses of efficacy, data were derived from subjects in the intent-to-treat (ITT) population, which was defined as all enrolled subjects who received at least one dose of MAS XR and underwent at least one baseline and one postbaseline assessment. The safety sample included all subjects who enrolled and initiated washout and/or received MAS XR. All continuous variables were summarized by descriptive statistics, and mean changes from baseline to each postbaseline visit and end point were analyzed using one-sample t tests with α=.05. All categorical data were described in terms of number of responses and percentages for each category. Descriptive statistics were generated for subjects in three previous treatment categories (no previous treatment, previous stimulant treatment, and nonstimulant treatment), but statistical comparisons between these groups were not performed. Similarly, descriptive statistics with regard to change from baseline in the primary efficacy variable (ADHD-RS-IV scores) were generated based on the final MAS XR dose administered; statistical comparisons between these dose groups were not performed. The CGI-I ratings were described for the standard response categories and also dichotomized into two categories: much improved/very much improved and not improved. All statistical analyses were performed using SAS ® for Windows version 6.12 or higher (SAS Institute, Cary, NC).
FINDINGS
Subjects
Demographic and baseline characteristics of all enrolled subjects are presented in Table 1 . This is the largest adult ADHD trial conducted to date. Of the 725 enrolled subjects, 387 had no previous treatment, 281 had received previous stimulant treatment, and 57 had received previous nonstimulant treatment. At baseline, the previous treatment groups were largely similar with regard to age, race, and ADHD symptom severity. Slightly larger proportions of subjects in the previous nonstimulant treatment category met criteria for ADHD combined subtype than in the other two previous treatment categories. Most subjects (548/725, 75.5%) reported a history of a clinically significant medical condition, with 468 of these subjects (64.5%) experiencing a currently ongoing condition, including conditions commonly seen in mature adults (most subjects were >30 years of age) such as acid reflux, irritable bowel syndrome, osteoarthritis, and elevated cholesterol. A total of 38 subjects (5.2%) had a history of or an ongoing Axis I or II psychiatric comorbidity.
Five hundred eighty-three subjects completed the 10-week study; 23 withdrew consent, 50 withdrew because of adverse events, and 69 withdrew for other reasons (including protocol violations and loss to follow-up). Of the enrolled subjects, 702 subjects met criteria for inclusion in the ITT population.
MAS XR Dosing
The mean length of exposure to open-label MAS XR was 71.0 days. The initial MAS XR dose for all subjects was 20 mg/day. At study visit 2, mean dose for the entire cohort was 19.3 mg/day, which reflects treatment initiation of all subjects receiving MAS XR 20 mg/day. Mean MAS XR dose increased and stabilized for all subgroups during the second half of the study (visits 4 and 5), reflecting the dose optimization process. At the final study visit, mean MAS XR dose was 37.2 mg/day (median=38.6 mg/day), with similar average doses received by the no previous treatment, previous stimulant treatment, and previous nonstimulant treatment subgroups (34.9, 39.9, and 39.7 mg/day, respectively). For the cohort as a whole, final MAS XR dose for most subjects was 30 mg/day (n=154), 40 mg/day (n=163), or 60 mg/day (n=141); fewer subjects received 10 mg/day (n=41), 20 mg/day (n=111), or 50 mg/day (n=92). Figure 1 illustrates mean total ADHD-RS-IV scores observed throughout the study in the ITT population. During week 1 of treatment when all subjects received MAS XR 20 mg/day, statistically significant improvements from baseline ADHD-RS-IV total scores emerged (P<.0001) and continuing improvements were seen throughout the remainder of the 10-week study period (Figure 1 ). At study end point, mean ADHD-RS-IV total scores for the entire ITT cohort and among prior treatment subgroups ( Figure 2 ) were decreased significantly (range: -18.8 to -21.6; all P<.0001) compared with baseline, and ADHD-RS-IV scores at end point were comparable between the no previous treatment, previous stimulant treatment, and previous nonstimulant treatment subgroups (12.7, 13.1, and 15.1 unit points, respectively). Similarly, significant decreases from baseline (all P<.0001) of comparable magnitude were seen at end point among the previous treatment subgroups in ADHD-RS-IV hyperactivity/impulsivity and inattentive subscale scores ( Figure 2 ). ADHD-RS-IV scores were also stratified by final dose of MAS XR received. Figure 3 illustrates change from baseline mean total ADHD-RS-IV scores observed retrospectively at each study visit, with subjects grouped according to the final MAS XR dose they were given. ADHD symptom relief was significantly reduced from baseline, regardless of dose; mean changes were numerically comparable among subjects receiving doses ranging from 10-60 mg/day. (No statistical comparisons among the dose groups were conducted.) Subjects whose final MAS XR dose was 60 mg/day showed somewhat higher ADHD-RS-IV scores at baseline (mean: 34.2 unit points) compared to subjects given the lower doses (range, baseline mean ADHD-RS-IV: 31.2-33.2 unit points) and it seems possible that this may have influenced the degree of symptom relief observed among these subjects.
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CGI-I Ratings
At study end point, most subjects obtained CGI-I ratings of much/very much improved (522/702; 74.4%; Figure 4) . Proportions of subjects rated as much/very much improved were largely comparable among the no previous treatment, previous stimulant treatment, and previous nonstimulant treatment subgroups (72.7%, 77.2%, and 71.1%, respectively). Only six subjects (6/702, 0.9%) were considered "much worse." No subjects were Change From Baseline, ADHD-RS-IV Total Score considered "very much worse" at end point.
Quality-of-Life Results
SF-36 Version 2
At study end point, subjects reported significant improvement from baseline (all P<.0001) in all quality-of-life domains measured by the SF-36 version 2 except bodily pain (P=.1431; Figure 5 ). Of note, robust improvements from baseline were seen in the role-emotional, vitality, social functioning, and mental health SF-36 domains with 10 weeks of MAS XR exposure (P<.0001). The no previous treatment and previous stimulant treatment subgroups exhibited similar, consistently significant (P<.01) improvements across seven of the eight domains (the exception being bodily pain). Significant (P<.05) improvement from baseline was seen on six of the eight domains (excepting bodily pain and general health) for the previous nonstimulant treatment subgroup.
Medication Satisfaction Survey
Overall, 70.6% of subjects strongly agreed or agreed that they were satisfied with MAS XR treatment (Table 2) . Most subjects reported satisfaction with once-daily dosing (88.5%) and ease of the medication regimen (92.0%). Moreover, most patients reported rarely skipping or missing a dose (86.4%).
Large proportions of subjects who received MAS XR reported that they felt satisfied with their behavior and ability to pay attention (67.6% and 67.4%, respectively) and most (64.7%) felt satisfied with the duration of the MAS XR therapeutic effect. Just over half of the subjects (51.3%) reported perceived improvements in social interactions during MAS XR treatment.
Safety and Tolerability
Treatment-emergent adverse events considered possibly related to MAS XR that were reported in ≥5% of subjects are summarized in Table 3 and included decreased appetite and dry mouth (19.2% each), insomnia (17.8%), headache (16.8%), and weight loss (11.0%). Most adverse events reported were mild or moderate in intensity. A total of 50 severe adverse events considered possibly or probably related to MAS XR were reported in 35 subjects; headache (n=6), irritability (n=3) and insomnia (n=9) were the most common severe adverse events, with all other severe adverse events reported one or two times. One serious adverse event (a respiratory, thoracic, and mediastinal disorder seen in a 31-year-old white woman) occurred during the study; it was considered unrelated to study medication. Fifty (6.9%) subjects discontinued from the study because of treatment-emergent adverse events. The most common adverse events contributing to discontinuation during MAS XR treatment were increased heart rate (n=10; 1.4%), elevated blood pressure, and insomnia (n=6; 0.8% each); all other adverse events related to discontinuation were seen in four or fewer subjects each.
In general, overall changes in laboratory values, ECGs, physical examination results, and vital signs were not clinically significant during treatment. At end point minimal average changes in pulse (5.2 beats per minute [bpm]), systolic blood pressure (SBP; 0.9 Change From Baseline ADHD-RS-IV Total Scor mm Hg), and diastolic blood pressure (DPB; 1.4 mm Hg) were seen; none of these changes was judged to be clinically significant. Similarly, at end point average changes in PR interval (-4.1 msec), QRS interval (-1.1 msec), QT interval (-11.4 msec), and QTc interval (4.9 msec) were small and not considered clinically significant. Most subjects exhibited vital signs and ECG measures considered within the normal range throughout the 10-week treatment period. At the last clinic visit (week 10) a total of 19 subjects (3.3%) exhibited heart rate >100 bpm, 19 (3.3%) subjects had DBP >90 mm Hg, and 25 subjects (4.4%) had SBP readings >140 mm Hg. With regard to subjects with outlier ECG measures, five (0.9%) had a PR interval >200 msec, eight (1.4%) had a QRS interval >120 msec, zero (0.0%) had a QT interval >450 msec or a QTc interval >500 msec, and two (0.4%) displayed a >60 msec increase in QTc interval from baseline.
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DISCUSSION
In a broad sample of adults with ADHD in community practice-based settings, 10 weeks of MAS XR treatment yielded significant symptomatic improvement, as measured by the ADHD-RS-IV and CGI-I scales. The results seen here are consistent with levels of efficacy seen with MAS XR in other, more highly selected adult patient samples, as well as in adolescents and primary school-age children with ADHD. Most adverse events were mild or moderate in intensity, and the drug-related adverse events reported during the long-term study were similar to what has been previously reported for MAS XR.
The symptom management seen here with MAS XR in adults with ADHD in naturalistic community practice settings is in line with the effects seen in more highly selected samples of adult subjects. 15 At the end of the 10-week treatment period, mean ADHD-RS-IV total scores for patients receiving MAS XR 10 to 60 mg were significantly improved (-19.8 unit points from baseline; 60.4%), and significant improvements were seen on both the inattentive and hyperactivity/impulsivity ADHD-RS-IV subscales. This magnitude of improvement from baseline is similar to that seen among a more highly selected sample of adult patients with 18 months of MAS XR treatment (~-18 unit points). 15 The robust improvement seen here is also similar to that described in a number of previous reports of long-term efficacy of stimulant therapy seen in adolescent and primary school-age children with ADHD. 20, 21 At the end of the 10-week study period, overall disease severity was rated as much or very much improved for nearly 75% of participants. This is the first investigation of quality-of-life improvements in adults with ADHD treated with stimulants. The study found that after 10 weeks of optimal MAS XR dosing, most subjects reported perceived improvements across all domains assessed by the SF-36 version 2. In line with use of stimulant therapy, on average, subjects reported improved vitality and general health. The largest improvements, however, were seen in the role-emotional vitality, social functioning, and mental health domains. It seems likely that improvements in these domains may be related to reductions in ADHD symptoms rather than stimulant use per se. In line with this, subjects also reported perceived improvements in their own behavior and attention following initiation of MAS XR therapy and improvements in their social interactions. As subjects perceived changes in their own behavior while taking MAS XR, it is likely that such improvements were clinically significant. Given the magnitude of improvement seen across multiple quality-of-life domains following only 10 weeks of treatment, it will be interesting to examine the potential impact of longer-term MAS XR therapy on qualityof-life and relevant patient outcomes currently being assessed in the ongoing 20-week extension phase of the QU.E.S.T. investigation. While the study found that improvements in certain quality of life domains were of smaller magnitude among the previous nonstimulant treatment subgroup, the reasons for this finding and the clinical impact of such differences are unclear. The small number of subjects in the previous nonstimulant treatment subgroup (n=57) makes drawing conclusions based on the current observations difficult. Potential factors that might account for the difference between this and the other subgroups include the presence of different or a greater number of medical or psychiatric comorbidities, or a distinct ADHD symptom or subtype profile. In the current cohort, a somewhat greater proportion of subjects receiving previous nonstimulant treatment were diagnosed with ADHD combined subtype (68%) versus in the no previous treatment (57.1%) or the previous stimulant treatment (51.6%) subgroups. Safety and tolerability outcomes seen here are also in line with those seen in other trials of stimulant therapy for ADHD. Changes in other safety parameters examined, such as vital signs and ECG assessments, were also generally not clinically significant; small increases in pulse (4 bpm) and systolic and diastolic blood pressure (1.0 and 1.5 mm Hg, respectively) were seen. The most common adverse event considered related to MAS XR and contributing to discontinuation was increased heart rate (n=10). Overall, relatively few subjects discontinued the 10-week trial due to adverse events (50 of 725; 6.9%).
Some differences in magnitude and nature of therapeutic response were observed between subjects in the previous nonstimulant treatment subgroup and subjects in the no previous treatment and previous stimulant treatment subgroups. Subjects in the previous nonstimulant treatment subgroup (n=52) generally responded as robustly to MAS XR therapy as did subjects in the other subgroups, marked by similar end point ADHD-RS-IV total scores and a similar magnitude of improvement from baseline. However, previous nonstimulant treatment subjects reported lesser overall perceived improvements in quality of life and failed to report statistically significant improvement from baseline in one domain (general health; P=.0926), whereas the other two subgroups reported robust improvements (P<.0001) despite similar scores at baseline. The reasons for such differences are not clear and may be related to variables not captured in the current analysis, such as presence of comorbid psychiatric or medical illnesses, possible reasons for previous nonuse of stimulant therapy. However, because the previous nonstimulant subgroup contained only 52 subjects in the current interim analysis, it is difficult to draw firm conclusions about differences in their outcomes with MAS XR and possible underlying causes. Results may differ upon analysis of the larger subject population and with longer-term treatment, targeted to include 900 subjects and to extend to a total of 30 weeks; examination of the final results is likely to clarify these questions.
Limitations
Because the sample of adult subjects eligible for inclusion here was more inclusive than in earlier, controlled investigations of MAS XR and other stimulant therapies in adults, we believe that our findings accurately reflect what may be seen with similar patients in real-world settings. The current subject cohort was generally similar to those from controlled trials of stimulant therapy in adults with ADHD with respect to age, race, gender, and ADHD history. 11, 13, 14 However, it was marked by a large proportion of subjects (~65%) with an ongoing, clinically significant medical condition, including but not limited to such common problems as acid reflux, irritable bowel syndrome, osteoarthritis, and elevated cholesterol. Moreover, the study included 38 subjects with a history of or an ongoing psychiatric Axis I or II comorbidity, unlike the more selected patient samples in controlled trials where psychiatric comorbidity is typically an exclusionary factor. Given these differences in this patient population compared to a controlled study, the efficacy and tolerability seen here with MAS XR are quite similar in nature and magnitude to that described in previous controlled trials. This suggests that MAS XR may be useful in a broad patient population that may include individuals with medical comorbidities and certain, less severe psychiatric comorbidities that do not contraindicate the use of MAS XR.
The current investigation is not without limitations. The open-label nature of the current study warrants that the outcomes described here be interpreted with a certain level of caution. Moreover, the subject population was limited to adults in the community with ADHD who were otherwise healthy. The dosing plan for the study may not reflect real-world approaches toward dose optimization. All subjects initiated treatment at 20 mg/day; most clinicians might choose to initiate patients with a 10-mg/day dose. Moreover, changes in dose were only made at weekly intervals; in the noninvestigatory setting, dose changes might occur over shorter intervals. Such differences, however, do not seem likely to appreciably alter the overall pattern of outcomes seen here compared with what might be seen with other dose optimization strategies. Efficacy and safety were examined over 10 weeks; effects of MAS XR over longer treatment periods were not characterized and may differ from the pattern of results described here.
CONCLUSION
The findings in the current study indicate that MAS XR at doses of up to 60 mg/day yields rapid and significant improvements in ADHD symptoms and quality of life in adults with ADHD in a realworld community practice setting. Further research on the impact of long-term MAS XR therapy on outcomes in adult patients is warranted. CNS
